1. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of Patient-Reported Outcome (PRO) Measures in Oncology Studies EMA/CHMP/292464/2014. London: European Medicines Agency;2016. https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed 1 December 2020.
2. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: US Food and Drug Administration;2009. https://www.fda.gov/media/77832/download. Accessed 1 December 2020.
3. Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care. 2005;43:493–9. https://doi.org/10.1097/01.mlr.0000160419.27642.a8.
4. Food and Drug Administration. Discussion document for patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Silver Spring, MD: US Food and Drug Administration;2018. https://www.fda.gov/media/116281/download. Accessed 4 August 2020.
5. Matza LS, Patrick DL, Riley AW, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16:461–79. https://doi.org/10.1016/j.jval.2013.04.004.